Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. raised its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 67.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,468 shares of the company’s stock after purchasing an additional 7,421 shares during the quarter. Victory Capital Management Inc.’s holdings in Atossa Therapeutics were worth $117,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lincoln National Corp acquired a new position in Atossa Therapeutics in the first quarter valued at $28,000. Kestra Advisory Services LLC acquired a new position in Atossa Therapeutics in the first quarter valued at $29,000. XTX Topco Ltd acquired a new position in Atossa Therapeutics in the first quarter valued at $43,000. GSA Capital Partners LLP acquired a new position in Atossa Therapeutics in the first quarter valued at $48,000. Finally, UBS Group AG purchased a new stake in shares of Atossa Therapeutics in the first quarter valued at about $55,000. Institutional investors own 28.41% of the company’s stock.

In related news, Director Gregory L. Weaver sold 107,497 shares of the business’s stock in a transaction dated Friday, July 2nd. The shares were sold at an average price of $5.58, for a total transaction of $599,833.26. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 3.98% of the stock is currently owned by insiders.

Shares of NASDAQ:ATOS opened at $3.28 on Tuesday. The company has a market cap of $415.32 million, a price-to-earnings ratio of -2.47 and a beta of 2.23. The firm’s 50-day simple moving average is $3.72 and its 200-day simple moving average is $3.56. Atossa Therapeutics, Inc. has a fifty-two week low of $0.81 and a fifty-two week high of $9.80.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Thursday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.02).

About Atossa Therapeutics

Atossa Therapeutics, Inc operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65.

Further Reading: What is the Stochastic Momentum Index (SMI)?

Want to see what other hedge funds are holding ATOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atossa Therapeutics, Inc. (NASDAQ:ATOS).

Institutional Ownership by Quarter for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.